Advanced Organoids: New Avenues for Understanding Human Anatomy, Physiology and Development

A special issue of Organoids (ISSN 2674-1172).

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 2507

Special Issue Editors


E-Mail Website
Guest Editor
Institute of Anatomy and Cell Biology, University of Würzburg, 97070 Würzburg, Germany
Interests: vascular morphogenesis; endothelial barrier function angiogenesis; vasculogenesis; tumor vascularization; vascular stem cells; adult stem cells; cardiovascular regeneration
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Institute of Anatomy and Cell Biology, University of Würzburg, Koellikerstr. 6, 97070 Würzburg, Germany
Interests: organoids; pluripotent stem cells; vascularization; cellular reprogramming; gap junctions

Special Issue Information

Dear Colleagues,

In anatomy and cell biology, our understanding of the human body has historically relied on the dissection and description of body donor material, microscopic–histological studies of tissue section from different organs and rare embryonic and fetal samples, as well as on animal models and clinical observations. However, recent advancements in induced pluripotent stem cells, gene editing techniques, and organoid, assembloid, as well as embryoid cultures have revolutionized experimental research by providing unprecedented opportunities to directly study developing human tissues in vitro. Moreover, the genetic manipulation of pluripotent stem cells and their directed differentiation into different tissues and organ- or embryo-like structures has developed new possibilities for researchers.

The aim of this Special Issue of Organoids is to present reviews and original articles on how advanced human 3D tissue culture models can improve our understanding of human anatomy, physiology, and development. We welcome contributions from participants of the annual meeting of the "Anatomische Gesellschaft" in Würzburg, Germany, in September 2023, as well as from other esteemed research groups working on this topic.

Prof. Dr. Süleyman Ergün
Dr. Philipp Wörsdörfer
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Organoids is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anatomy
  • embryology
  • histology
  • organoids
  • assembloids
  • embryoids
  • blastoids
  • pluripotent stem cells

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 50653 KiB  
Article
Analysis of Osteosarcoma Cell Lines and Patient Tissue Using a 3D In Vivo Tumor Model—Possible Effects of Punicalagin
by Anna Rebecca Dorn, Sara Neff, Sophia Hupp, Melissa Engelhardt, Eric Pion, Ulrich Lenze, Carolin Knebel, Anna Duprée, Simone Schewe, Markus Weber, Christian Wulbrand, Axel Hillmann, Florian Weber, Phillip Clarke, Philipp Kainz, Thiha Aung and Silke Haerteis
Organoids 2024, 3(1), 35-53; https://doi.org/10.3390/organoids3010004 - 04 Mar 2024
Viewed by 948
Abstract
Osteosarcomas are the most common primary malignant bone tumors and mostly affect children, adolescents, and young adults. Despite current treatment options such as surgery and polychemotherapy, the survival of patients with metastatic disease remains poor. In recent studies, punicalagin has reduced the cell [...] Read more.
Osteosarcomas are the most common primary malignant bone tumors and mostly affect children, adolescents, and young adults. Despite current treatment options such as surgery and polychemotherapy, the survival of patients with metastatic disease remains poor. In recent studies, punicalagin has reduced the cell viability, angiogenesis, and invasion in cell culture trials. The aim of this study was to examine the effects of punicalagin on osteosarcomas in a 3D in vivo tumor model. Human osteosarcoma biopsies and SaOs-2 and MG-63 cells, were grown in a 3D in vivo chorioallantoic membrane (CAM) model. After a cultivation period of up to 72 h, the tumors received daily treatment with punicalagin for 4 days. Weight measurements of the CAM tumors were performed, and laser speckle contrast imaging (LSCI) and a deep learning-based image analysis software (CAM Assay Application v.3.1.0) were used to measure angiogenesis. HE, Ki-67, and Caspase-3 staining was performed after explantation. The osteosarcoma cell lines SaOs-2 and MG-63 and osteosarcoma patient tissue displayed satisfactory growth patterns on the CAM. Treatment with punicalagin decreased tumor weight, proliferation, and tumor-induced angiogenesis, and the tumor tissue showed pro-apoptotic characteristics. These results provide a robust foundation for the implementation of further studies and show that punicalagin offers a promising supplementary treatment option for osteosarcoma patients. The 3D in vivo tumor model represents a beneficial model for the testing of anti-cancer therapies. Full article
Show Figures

Figure 1

17 pages, 12196 KiB  
Article
Visualization of Vascular Perfusion of Human Pancreatic Cancer Tissue in the CAM Model and Its Impact on Future Personalized Drug Testing
by Andreas Ettner-Sitter, Agata Montagner, Jonas Kuenzel, Kathrin Brackmann, Maximilian Schäfer, Robert Schober, Florian Weber, Thiha Aung, Christina Hackl and Silke Haerteis
Organoids 2024, 3(1), 1-17; https://doi.org/10.3390/organoids3010001 - 08 Jan 2024
Cited by 1 | Viewed by 1063
Abstract
Although significant improvements have been made in the treatment of pancreatic cancer, its prognosis remains poor with an overall 5-year survival rate of less than 10%. New experimental approaches are necessary to develop novel therapeutics. In this study, the investigation of pancreatic cancer [...] Read more.
Although significant improvements have been made in the treatment of pancreatic cancer, its prognosis remains poor with an overall 5-year survival rate of less than 10%. New experimental approaches are necessary to develop novel therapeutics. In this study, the investigation of pancreatic cancer tissue growth in the chorioallantoic membrane (CAM) model and the subsequent use of indocyanine green (ICG) injections for the verification of intratumoral perfusion was conducted. ICG was injected into the CAM vasculature to visualize the perfusion of the tumor tissue. The presence of metastasis was investigated through PCR for the human-specific ALU element in the liver of the chicken embryo. Additionally, the usage of cryopreserved pancreatic tumors was established. Intratumoral perfusion of tumor tissue on the CAM was observed in recently obtained and cryopreserved tumors. ALU-PCR detected metastasis in the chick embryos’ livers. After cryopreservation, the tissue was still vital, and the xenografts generated from these tumors resembled the histological features of the primary tumor. This methodology represents the proof of principle for intravenous drug testing of pancreatic cancer in the CAM model. The cryopreserved tumors can be used for testing novel therapeutics and can be integrated into the molecular tumor board, facilitating personalized tumor treatment. Full article
Show Figures

Graphical abstract

Back to TopTop